IP Library Granted Patent US 12,516,110
Granted Patent B2
US 12,516,110 · App. 17/549,809 · Granted Jan 6, 2026

CTHRC1-specific antibody and use thereof

Inventors: Sang Seok Koh (Busan, KR); Min Kyung Kang (Busan, KR); So Yeon Park (Singapore, KR)
Assignees: PRESTIGE BIOPHARMA LIMITED; PRESTIGE BIOPHARMA IDC CO., LTD.
C07K16/18A61P35/00G01N33/57488A61K39/00A61K2039/505C07K2317/24C07K2317/565C07K2317/92G01N2333/4704
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,516,110
App. No.
17/549,809
Granted
Jan 6, 2026
Kind
B2
Abstract

The present invention relates to a novel antibody which binds to CTHRC1 and use thereof.

Claims (21)

1 . An antibody that specifically binds to collagen triple helix repeat containing-1 (CTHRC1) protein, which comprises: (a) a heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 11, a heavy chain CDR2 of SEQ ID NO: 12, and a heavy chain CDR3 of SEQ ID NO: 13; and

(b) a light chain variable region comprising a light chain CDR1 of SEQ ID NO: 14, a light chain CDR2 of SEQ ID NO: 15, and a light chain CDR3 of SEQ ID NO: 16.

2 . The antibody of claim 1 , wherein the heavy chain variable region consists of an amino acid sequence of SEQ ID NO: 17 or 25, and the light chain variable region consists of an amino acid sequence of SEQ ID NO: 19, or 27.

3 . A polynucleotide encoding the antibody of claim 1 .

4 . An expression vector comprising the polynucleotide of claim 3 .

5 . A host cell comprising the expression vector of claim 4 .

6 . A pharmaceutical composition for preventing or treating cancer, comprising the antibody of claim 1 .

7 . The composition of claim 6 , wherein the cancer is selected from the group consisting of pancreatic cancer, ovarian cancer, breast cancer, melanoma, liver cancer, stomach cancer, lung cancer, colorectal cancer, oral cancer, cervical cancer, and bladder cancer.

8 . A method of providing information for diagnosing cancer, comprising detecting CTHRC1 protein in a biological sample isolated from a subject suspected of having cancer through an antigen-antibody reaction, using the antibody of claim 1 .

9 . A method of providing information for predicting prognosis of cancer, comprising detecting CTHRC1 protein in a biological sample isolated from a subject suffering from cancer through an antigen-antibody reaction, using the antibody of claim 1 .

10 . A composition for diagnosing cancer or predicting prognosis of cancer, comprising the antibody of claim 1 .

11 . A kit for diagnosing cancer or predicting prognosis of cancer, comprising the composition of claim 10 .

12 . A kit for detecting CTHRC1, comprising the antibody of claim 1 .

13 . The kit of claim 12 , wherein the kit is in the form of ELISA (Enzyme-Linked Immunosorbent Assay).

14 . The kit of claim 13 , wherein the antibody is a capture antibody.

15 . The kit of claim 13 , wherein the ELISA is an indirect ELISA comprising:

(i) a polyclonal antibody that binds to CTHRC1;

(ii) a capture antibody in the form of the antibody that specifically binds to collagen triple helix repeat containing-1 (CTHRC1) protein, which comprises: (a) a heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 11, a heavy chain CDR2 of SEQ ID NO: 12, and a heavy chain CDR3 of SEQ ID NO: 13; and

(b) a light chain variable region comprising a light chain CDR1 of SEQ ID NO: 14, a light chain CDR2 of SEQ ID NO: 15, and a light chain CDR3 of SEQ ID NO: 16; and

(iii) an antibody bound to a detection-labeled IgG Fc.

16 . A method for detecting CTHRC1 protein in a sample, comprising detecting an CTHRC1 antigen-antibody complex using the antibody of claim 1 .

Assignments (4)
CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY DATA PREVIOUSLY RECORDED AT REEL: 67057 FRAME: 556. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Apr 23, 2024
From: PRESTIGE BIOPHARMA LIMITED
To: PRESTIGE BIOPHARMA LIMITED; PRESTIGE BIOPHARMA IDC CO., LTD.
Reel/Frame 067193/0670 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 10, 2024
From: PRESTIGE BIOPHARMA LIMITED
To: PRESTIGE BIOPHARMA IDC CO., LTD.
Reel/Frame 067057/0556 →
CHANGE OF NAME Recorded Apr 10, 2024
From: PRESTIGE BIOPHARMA PTE. LTD.
To: PRESTIGE BIOPHARMA LIMITED
Reel/Frame 067057/0562 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 6, 2022
From: SEOK KOH, SANG; KYUNG KANG, MIN; YEON PARK, SO
To: PRESTIGE BIOPHARMA PTE. LTD.
Reel/Frame 059837/0946 →
Priority Claims (1)
KR 10-2019-0070048 · Jun 13, 2019 · national
Continuity (2)
Continuation In Part PCTIB2020055561 · Jun 15, 2020
Related Publication 20220204599A1 · Jun 30, 2022
References Cited (27)
US 20100183512A1 · Qin et al. · 2010 [cited by applicant]
US 20170355756A1 · Julien · 2017 [cited by examiner]
JP 2012506253A · 2012 [cited by applicant]
KR 1020070030084 · 2007 [cited by applicant]
KR 1020110082669 · 2011 [cited by applicant]
KR 1020130094640 · 2013 [cited by applicant]
KR 1020140144934 · 2014 [cited by applicant]
WO WO2008068048A2 · 2008 [cited by examiner]
WO WO2014200134A1 · 2014 [cited by applicant]
KR20140144934A-Google Patents English Translation (Year: 2014). [cited by examiner]
Mariuzza (Annu. Rev. Biophys. Biophys. Chem., 16: 139-159, 1987) (Year: 1987). [cited by examiner]
McCarthy et al. (J. Immunol. Methods, 251(1-2): 137-149, 2001 (Year: 2001). [cited by examiner]
Lin et al. (African Journal of Biotechnology, 10(79):18294-18302, 2011) (Year: 2011). [cited by examiner]
Sakamoto et al (Enzyme-linked immunosorbent assay for the quantitative/qualitative analysis of plant secondary metabolites. J Nat Med. Jan. 2018;72(1):32-42. doi: 10.1007/s11418-017-1144-z. Epub Nov. 21, 2017. Erratum i… [cited by examiner]
Janeway et al (Immunobiology: The Immune System in Health and Disease. 5th edition. New York: Garland Science; 2001. The structure of a typical antibody molecule. Available from: https://www.ncbi.nlm.nih.gov/books/NBK27… [cited by examiner]
Cui X. et al., Inhibition of CTHRC-1 by its specific monoclonal antibody attenuates cervical cancer cells metastasis, Biomedicine & Pharmacotherapy, 2019, vol. 110, pp. 758-763. [cited by applicant]
Extended European Search Report issued May 23, 2023 in connection with European Application No. 20822106.9. [cited by applicant]
Park, E. H., Collagen triple helix repeat containing-1 promotes pancreatic cancer progression by regulating migration and adhesion of tumor cells, Carcinogenesis, vol. 00, No. 00, (2013) pp. 1-9. [cited by applicant]
Lee, J. et al., CTHRC1 promotes angiogenesis by recruiting Tie2-expressing monocytes to pancreatic tumors, Experimental & Molecular Medicine, vol. 48, No. e261, (2016) pp. 1-11. [cited by applicant]
Korea Research Institute of Bioscience And Biotechnology, Mechanistic Studies and Antibody Therapeutic Application of CTHRC1, A Novel Factor Expressed in Cancer Cells. Government Project Report) (2013) pp. 1-60. [cited by applicant]
International Search Report issued Nov. 3, 2020 in connection with PCT International Application No. PCT/IB2020/055561. [cited by applicant]
Derksen, P.W. et al., “Illegitimate WNT signaling promotes proliferation of multiple myeloma cells”, Proceedings of the National Academy of Sciences, 2004, vol. 101, No. 16, pp. 6122-6127. [cited by applicant]
Dirks, P.B., “Brain Tumor Stem Cells: Bringing Order to the Chaos of Brain Cancer”, Journal of Clinical Oncology, 2008, vol. 26. No. 17, pp. 2916-2924. [cited by applicant]
López-Lázaro, M., “The migration ability of stem cells can explain the existence of unknown primary site. Rethinking metastasis.”, Oncoscience, 2015, vol. 2, No. 5, pp. 467. [cited by applicant]
Ohno, S. et al., “Antigen-binding specificities of antibodies are primarily determined by seven residues of V [cited by applicant]
Tran, B. and Rosenthal M.A., “Survival comparison between glioblastoma multiforme and other incurable cancers”, Journal of Clinical Neuroscience, 2010, vol. 17, pp. 417-421. [cited by applicant]
Dec. 19, 2023 Office Action issued in connection with Russian Application No. 2021137558/10. [cited by applicant]